Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C59H84N18O14 |
Molecular Weight | 1269.4105 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC4=CNC=N4)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N6CCC[C@H]6C(=O)NNC(N)=O
InChI
InChIKey=BLCLNMBMMGCOAS-URPVMXJPSA-N
InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1
Molecular Formula | C59H84N18O14 |
Molecular Weight | 1269.4105 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 4 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00014Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/zoladex.html
Sources: http://www.drugbank.ca/drugs/DB00014
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/zoladex.html
Goserelin is a synthetic decapeptide analogue of LHRH. Goserelin acts as a potent inhibitor of pituitary gonadotropin secretion when administered in the biodegradable formulation. The result is sustained suppression of LH and serum testosterone levels. Goserelin is used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty. Goserelin is marketed under the brand names Zoladex, by AstraZeneca, or goserelin acetate.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1854 Sources: http://www.drugbank.ca/drugs/DB00014 |
|||
Target ID: CHEMBL612518 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1320049 |
0.82 nM [IC50] | ||
Target ID: CHEMBL1855 Sources: http://www.drugbank.ca/drugs/DB00014 |
1.6 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ZOLADEX Approved UseZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for:
Use in combination with flutamide for the management of locally confined carcinoma of the prostate
Use as palliative treatment of advanced carcinoma of the prostate Launch Date1997 |
|||
Palliative | ZOLADEX Approved UseZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for:
Use in combination with flutamide for the management of locally confined carcinoma of the prostate
Use as palliative treatment of advanced carcinoma of the prostate Launch Date1997 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.46 ng/mL |
3.6 mg single, subcutaneous dose: 3.6 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
2.84 ng/mL |
3.6 mg single, subcutaneous dose: 3.6 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.79 μg/L |
250 μg single, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
13.9 μg/L |
250 μg single, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
9.5 μg/L |
250 μg 1 times / day multiple, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: MULTIPLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
7.5 μg/L |
250 μg single, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
3 ng/mL |
3.6 mg single, subcutaneous dose: 3.6 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
8.85 ng/mL |
10.8 mg single, subcutaneous dose: 10.8 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.5 ng × day/mL |
3.6 mg single, subcutaneous dose: 3.6 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
27.8 ng × day/mL |
3.6 mg single, subcutaneous dose: 3.6 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
36.9 μg × h/L |
250 μg single, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
41.3 μg × h/L |
250 μg single, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
44 μg × h/L |
250 μg 1 times / day multiple, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: MULTIPLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
44.5 μg × h/L |
250 μg single, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.2 h |
250 μg single, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.3 h |
250 μg single, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
5 h |
250 μg 1 times / day multiple, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: MULTIPLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
4.6 h |
250 μg single, subcutaneous dose: 250 μg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
73% |
10.8 mg single, subcutaneous dose: 10.8 mg route of administration: Subcutaneous experiment type: SINGLE co-administered: |
GOSERELIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Co-administed with:: Chemotherapy Sources: |
unhealthy, 18 - 49 years n = 103 Health Status: unhealthy Condition: breast cancer Age Group: 18 - 49 years Sex: F Population Size: 103 Sources: |
Other AEs: Fatigue, Hot flashes... Other AEs: Fatigue (grade 2, 2 patients) Sources: Hot flashes (grade 2, 29 patients) Menses irregular (grade 2, 5 patients) Libido decreased (grade 2, 9 patients) Agitation (grade 2, 6 patients) Anxiety (grade 2, 9 patients) Depression (grade 2, 8 patients) Muscle pain (grade 2, 1 patient) Headache (grade 2, 12 patients) Sweating (grade 2, 10 patients) Thromboembolism (grade 4, 1 patient) Dryness vaginal (grade 2, 12 patients) Hot flashes (grade 3, 4 patients) Menses irregular (grade 3, 2 patients) Depression (grade 3, 1 patient) |
10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Co-administed with:: flutamide Sources: after 90 days of radiation therapy |
unhealthy, adult n = 231 Health Status: unhealthy Condition: Prostatic Carcinoma Age Group: adult Sex: M Population Size: 231 Sources: |
Other AEs: Diarrhea, Cystitis... Other AEs: Diarrhea (36%) Sources: Cystitis (16%) Bleeding rectal (14%) Proctitis (8%) Hematuria (7%) |
10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Co-administed with:: flutamide Sources: radiation therapy |
unhealthy, adult n = 231 Health Status: unhealthy Condition: Prostatic Carcinoma Age Group: adult Sex: M Population Size: 231 Sources: |
Other AEs: Gastrointestinal disorder (NOS), Bladder disorder NOS... Other AEs: Gastrointestinal disorder (NOS) (80%) Sources: Bladder disorder NOS (58%) Skin and subcutaneous conditions NEC (37%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Muscle pain | grade 2, 1 patient | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Co-administed with:: Chemotherapy Sources: |
unhealthy, 18 - 49 years n = 103 Health Status: unhealthy Condition: breast cancer Age Group: 18 - 49 years Sex: F Population Size: 103 Sources: |
Sweating | grade 2, 10 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Co-administed with:: Chemotherapy Sources: |
unhealthy, 18 - 49 years n = 103 Health Status: unhealthy Condition: breast cancer Age Group: 18 - 49 years Sex: F Population Size: 103 Sources: |
Dryness vaginal | grade 2, 12 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Co-administed with:: Chemotherapy Sources: |
unhealthy, 18 - 49 years n = 103 Health Status: unhealthy Condition: breast cancer Age Group: 18 - 49 years Sex: F Population Size: 103 Sources: |
Headache | grade 2, 12 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Co-administed with:: Chemotherapy Sources: |
unhealthy, 18 - 49 years n = 103 Health Status: unhealthy Condition: breast cancer Age Group: 18 - 49 years Sex: F Population Size: 103 Sources: |
Fatigue | grade 2, 2 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Co-administed with:: Chemotherapy Sources: |
unhealthy, 18 - 49 years n = 103 Health Status: unhealthy Condition: breast cancer Age Group: 18 - 49 years Sex: F Population Size: 103 Sources: |
Hot flashes | grade 2, 29 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Co-administed with:: Chemotherapy Sources: |
unhealthy, 18 - 49 years n = 103 Health Status: unhealthy Condition: breast cancer Age Group: 18 - 49 years Sex: F Population Size: 103 Sources: |
Menses irregular | grade 2, 5 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Co-administed with:: Chemotherapy Sources: |
unhealthy, 18 - 49 years n = 103 Health Status: unhealthy Condition: breast cancer Age Group: 18 - 49 years Sex: F Population Size: 103 Sources: |
Agitation | grade 2, 6 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Co-administed with:: Chemotherapy Sources: |
unhealthy, 18 - 49 years n = 103 Health Status: unhealthy Condition: breast cancer Age Group: 18 - 49 years Sex: F Population Size: 103 Sources: |
Depression | grade 2, 8 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Co-administed with:: Chemotherapy Sources: |
unhealthy, 18 - 49 years n = 103 Health Status: unhealthy Condition: breast cancer Age Group: 18 - 49 years Sex: F Population Size: 103 Sources: |
Anxiety | grade 2, 9 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Co-administed with:: Chemotherapy Sources: |
unhealthy, 18 - 49 years n = 103 Health Status: unhealthy Condition: breast cancer Age Group: 18 - 49 years Sex: F Population Size: 103 Sources: |
Libido decreased | grade 2, 9 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Co-administed with:: Chemotherapy Sources: |
unhealthy, 18 - 49 years n = 103 Health Status: unhealthy Condition: breast cancer Age Group: 18 - 49 years Sex: F Population Size: 103 Sources: |
Depression | grade 3, 1 patient | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Co-administed with:: Chemotherapy Sources: |
unhealthy, 18 - 49 years n = 103 Health Status: unhealthy Condition: breast cancer Age Group: 18 - 49 years Sex: F Population Size: 103 Sources: |
Menses irregular | grade 3, 2 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Co-administed with:: Chemotherapy Sources: |
unhealthy, 18 - 49 years n = 103 Health Status: unhealthy Condition: breast cancer Age Group: 18 - 49 years Sex: F Population Size: 103 Sources: |
Hot flashes | grade 3, 4 patients | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Co-administed with:: Chemotherapy Sources: |
unhealthy, 18 - 49 years n = 103 Health Status: unhealthy Condition: breast cancer Age Group: 18 - 49 years Sex: F Population Size: 103 Sources: |
Thromboembolism | grade 4, 1 patient | 3.6 mg 1 times / day steady, subcutaneous Recommended Dose: 3.6 mg, 1 times / day Route: subcutaneous Route: steady Dose: 3.6 mg, 1 times / day Co-administed with:: Chemotherapy Sources: |
unhealthy, 18 - 49 years n = 103 Health Status: unhealthy Condition: breast cancer Age Group: 18 - 49 years Sex: F Population Size: 103 Sources: |
Bleeding rectal | 14% | 10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Co-administed with:: flutamide Sources: after 90 days of radiation therapy |
unhealthy, adult n = 231 Health Status: unhealthy Condition: Prostatic Carcinoma Age Group: adult Sex: M Population Size: 231 Sources: |
Cystitis | 16% | 10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Co-administed with:: flutamide Sources: after 90 days of radiation therapy |
unhealthy, adult n = 231 Health Status: unhealthy Condition: Prostatic Carcinoma Age Group: adult Sex: M Population Size: 231 Sources: |
Diarrhea | 36% | 10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Co-administed with:: flutamide Sources: after 90 days of radiation therapy |
unhealthy, adult n = 231 Health Status: unhealthy Condition: Prostatic Carcinoma Age Group: adult Sex: M Population Size: 231 Sources: |
Hematuria | 7% | 10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Co-administed with:: flutamide Sources: after 90 days of radiation therapy |
unhealthy, adult n = 231 Health Status: unhealthy Condition: Prostatic Carcinoma Age Group: adult Sex: M Population Size: 231 Sources: |
Proctitis | 8% | 10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Co-administed with:: flutamide Sources: after 90 days of radiation therapy |
unhealthy, adult n = 231 Health Status: unhealthy Condition: Prostatic Carcinoma Age Group: adult Sex: M Population Size: 231 Sources: |
Skin and subcutaneous conditions NEC | 37% | 10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Co-administed with:: flutamide Sources: radiation therapy |
unhealthy, adult n = 231 Health Status: unhealthy Condition: Prostatic Carcinoma Age Group: adult Sex: M Population Size: 231 Sources: |
Bladder disorder NOS | 58% | 10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Co-administed with:: flutamide Sources: radiation therapy |
unhealthy, adult n = 231 Health Status: unhealthy Condition: Prostatic Carcinoma Age Group: adult Sex: M Population Size: 231 Sources: |
Gastrointestinal disorder (NOS) | 80% | 10.8 mg 1 times / day steady, subcutaneous Recommended Dose: 10.8 mg, 1 times / day Route: subcutaneous Route: steady Dose: 10.8 mg, 1 times / day Co-administed with:: flutamide Sources: radiation therapy |
unhealthy, adult n = 231 Health Status: unhealthy Condition: Prostatic Carcinoma Age Group: adult Sex: M Population Size: 231 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Anxiety and mood disorders associated with gonadotropin-releasing hormone agonist therapy. | 1997 |
|
[A case of fulminant hepatitis caused by antiandrogen, flutamide in a patient with prostate cancer]. | 1997 Jul |
|
Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma. | 1999 Mar |
|
Death due to liver failure during endocrine therapy for premenopausal breast cancer. | 2010 Aug |
Sample Use Guides
ZOLADEX (Goserelin), at a dose of 3.6 mg, should be administered subcutaneously every 28 days into the anterior abdominal wall below the navel line using an aseptic technique under the supervision of a physician
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1320049
Goserelin significantly inhibited LNCaP cell proliferation at doses between 10(-9)-10(-6) M.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:04:24 GMT 2023
by
admin
on
Sat Dec 16 16:04:24 GMT 2023
|
Record UNII |
0F65R8P09N
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1910
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
||
|
LIVERTOX |
NBK548740
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
||
|
NDF-RT |
N0000175655
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
||
|
WHO-VATC |
QL02AE03
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
||
|
WHO-ATC |
L02AE03
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
||
|
NDF-RT |
N0000175654
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB00014
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201247
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY | |||
|
DTXSID7048297
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY | |||
|
65807-02-5
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY | |||
|
7606
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY | |||
|
3879
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY | |||
|
1327
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY | |||
|
0F65R8P09N
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY | |||
|
SUB07962MIG
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY | |||
|
5311128
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY | |||
|
0F65R8P09N
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY | |||
|
D017273
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY | |||
|
100000084238
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY | |||
|
Goserelin
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY | |||
|
m5832
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY | Merck Index | ||
|
Z-21
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY | |||
|
C1374
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY | |||
|
50610
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY | RxNorm | ||
|
5943
Created by
admin on Sat Dec 16 16:04:25 GMT 2023 , Edited by admin on Sat Dec 16 16:04:25 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> AGONIST |
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||